← Back to Search

Retinoid

S6G5T-3 for Acne Vulgaris

Phase 1
Waitlist Available
Research Sponsored by Sol-Gel Technologies, Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 14 days
Awards & highlights
All Individual Drugs Already Approved
Approved for 5 Other Conditions
No Placebo-Only Group

Summary

This trial tests a new acne cream called S6G5T-3 to see how much of it gets into the body compared to an existing cream. It involves people aged 12 and older who have acne.

Eligible Conditions
  • Acne Vulgaris
  • Acne

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~14 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 14 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Pharmacokinetics of S6G5T-3 as measured by the maximum observed plasma concentration

Side effects data

From 2019 Phase 3 trial • 434 Patients • NCT03761810
10%
Application site pain
4%
Application site dryness
3%
Application site erythema
3%
Application site exfoliation
2%
Application site pruritus
2%
Application site dermatitis
1%
Application site photosensitivity
1%
Nasopharyngitis
100%
80%
60%
40%
20%
0%
Study treatment Arm
S6G5T-3
S6G5T-8 Vehicle Cream

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: S6G5T-3Experimental Treatment1 Intervention
topical cream
Group II: Retin-A® 0.1% CreamActive Control1 Intervention
topical cream
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
S6G5T-3
2018
Completed Phase 3
~1650

Find a Location

Who is running the clinical trial?

Sol-Gel Technologies, Ltd.Lead Sponsor
14 Previous Clinical Trials
4,201 Total Patients Enrolled
3 Trials studying Acne Vulgaris
1,584 Patients Enrolled for Acne Vulgaris
~10 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top